Le Lézard
Classified in: Environment, Health
Subjects: SVY, ENI

Health Systems Can Lower Operational Costs and Reduce Environmental Impact with CareAdvantage from the Johnson & Johnson Medical Devices Companies


SOMERVILLE, N.J., Sept. 27, 2017 /PRNewswire/ -- With health systems focused on finding new ways to address their impact on the environment and reduce costs, CareAdvantage from the Johnson & Johnson Medical Devices Companies* now has a new Sustainability capability. Designed to help health systems achieve specific environmental, waste management, cost savings, and sustainable purchasing goals, this offering from the Johnson & Johnson Medical Devices Companies (JJMDC)** draws on more than 25 years of sustainability commitments by the Johnson & Johnson Family of Companies, including its leadership in medical device reprocessing and its deep commitment to its Health for Humanity 2020 Goals.

 (PRNewsfoto/Johnson & Johnson Medical [...])

There is a growing demand for sustainability strategies in the healthcare ecosystem among U.S. health system executives and operating room clinicians, according to insights from a new JJMDC survey, called the Voices for Value Insights Seriesii. The survey found that nine out of 10 clinicians (92%) and health system executives (88%) agree that sustainability provides long-term cost savings. The majority also agree that sustainability provides additional benefits, such as protecting the environment (76%), improving patient care (73%), and increasing the ability to manage risk and regulatory performance (68%). Nearly all (95%) believe that environmental sustainability contributes to the value of care delivered in their health system. The survey was conducted online between September 7 and 13, 2017 among 92 executives and clinicians at large U.S. health systems.

"Sustainability is critically important to Intermountain Healthcare, but recycling alone is not going to help us reach our goals," said Steve Bergstrom, Director of Sustainability at Intermountain Healthcare. "Our collaboration helps us reduce waste and operating room expenses through a more circular systems approach that is saving hundreds of thousands of dollars on medical device costs and diverting tens of thousands of pounds of Intermountain waste from landfills each year."

The CareAdvantage Sustainability capability enables best-in-class reprocessing across a broad spectrum of product categories, to include both JJMDC as well as non-JJMDC reprocessed single-use devices. It also includes practical tools and educational resources to help health systems create sustainability programs with financial and environmental benefits while implementing best practices for measuring and communicating the value of sustainability in healthcare.

The CareAdvantage Sustainability capability can also help purchasing and sustainability teams in healthcare delivery systems meet their Environmental Preferable Purchasing (EPP) goals. Specific expertise is designed to help healthcare delivery systems build a consistent approach to EPP assessments. In addition, through EARTHWARDS®, the Johnson & Johnson approach for encouraging the development of more sustainable products, health systems can access devices which have been designed with factors such as reducing materials, minimizing packaging, and reducing energy usage in mind.

"Drawing on our extensive experience in sustainability, we can provide health systems with a broad portfolio of sustainably sourced medical devices to help them meet their commitment to environmental stewardship efficiently and cost effectively," said Melinda Thiel, Vice President, Customer Marketing & Solutions at JJMDC. "This is just one element of how we approach customer needs, which starts with listening and leads to a holistic, tailored approach to help them reach their goals and deliver measurable results."

For more information about CareAdvantage and its capabilities, including Sustainability, visit www.careadvantagejjmdc.com. Join the discussion about value-based care on Voices for Value on LinkedIn.

About the Johnson & Johnson Medical Devices Companies

The Johnson & Johnson Medical Devices Companies' purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs and research and development capabilities in surgical technology, orthopaedics, cardiovascular and specialty solutions with an offering directed at delivering clinical and economic value to health care systems worldwide.

About Johnson & Johnson Health Care Systems Inc.

Johnson & Johnson Health Care Systems Inc. (JJHCS) provides contracting, supply chain, business services, and strategic solutions to customers and commercial intermediaries of U.S.-based Johnson & Johnson companies, including hospital systems, health plans, distributors, wholesalers, purchasing organizations, government payer programs, and government healthcare institutions in the U.S. JJHCS also engages with customers to provide streamlined supply chain services for our products that seamlessly integrate with customer operations, address shared evolving market challenges to value-based care, and develop innovative solutions that improve patient care and access.

* CareAdvantage from the Johnson & Johnson Medical Devices Companies is offered through Johnson & Johnson Health Care Systems Inc.

** The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson's Medical Devices segment.

i Sanbon BJ. Hospitals save millions with sustainability programs, cut back on waste. Healthcare Finance. March 14, 2017. http://www.healthcarefinancenews.com/news/hospitals-save-millions-sustainability-programs-cut-back-waste

ii The survey was conducted online between September 7 and 13, 2017 among 92 executives and clinicians at large U.S. health systems.

080985-170922

SOURCE Johnson & Johnson Medical Devices Companies


These press releases may also interest you

at 21:45
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

at 21:30
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...

at 19:30
Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology...

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...



News published on and distributed by: